Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Finished Goods (2022 - 2025)

InMed Pharmaceuticals' Finished Goods history spans 4 years, with the latest figure at $378636.0 for Q4 2025.

  • For Q4 2025, Finished Goods fell 43.92% year-over-year to $378636.0; the TTM value through Dec 2025 reached $378636.0, down 43.92%, while the annual FY2025 figure was $676178.0, 19.58% down from the prior year.
  • Finished Goods reached $378636.0 in Q4 2025 per INM's latest filing, up from $295809.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $927182.0 in Q3 2024 to a low of $231956.0 in Q1 2025.
  • Average Finished Goods over 4 years is $596273.0, with a median of $582161.0 recorded in 2022.
  • Peak YoY movement for Finished Goods: soared 88.73% in 2023, then crashed 68.1% in 2025.
  • A 4-year view of Finished Goods shows it stood at $605956.0 in 2022, then decreased by 7.94% to $557859.0 in 2023, then grew by 21.03% to $675164.0 in 2024, then plummeted by 43.92% to $378636.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Finished Goods are $378636.0 (Q4 2025), $295809.0 (Q3 2025), and $676178.0 (Q2 2025).